子宮內膜異位症治療藥的全球市場

Endometriosis Drugs

出版日期: 2023年03月01日 | 出版商:

Global Industry Analysts, Inc. | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

子宮內膜異位症治療藥的全球市場2030年將達到33億美元

在COVID-19後改變的商務環境中，2022年27億美元的子宮內膜異位症治療藥的全球市場，在2030年前將達到33億美元的規模，在2022年～2030年預計將以完成年複合成長率2.6％的速度成長。本報告所分析之市場區隔之一的荷爾蒙療法年複合成長率將記錄3％，到分析期間結束時達到20億美元。考慮疫情後的復甦趨勢，止痛藥領域今後8年的年複合成長率將修正為2％。

美國市場估算為7億7,780萬美元，中國則將以年複合成長率2.4％增長

美國的子宮內膜異位症治療藥市場在2022年估算為77,780萬美元。作為世界第2大經濟大國的中國，在2022年～2030年年複合成長率預計將為2.4％，在2030年將達到5億8,010萬美元的市場規模。其他熱門的地區市場有日本和加拿大，在2022年～2030年預計將各以2.3％和2％的速度成長。在歐洲市場中，德國將以年複合成長率2.4％成長。

調查對像企業範例

AbbVie Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Bayer AG
Debiopharm Group
Evotec AG
Kissei Pharmaceutical Co. Ltd.
Neurocrine Biosciences Inc.
ObsEva SA
Pfizer Inc.
Repros Therapeutics Inc.
Takeda Pharmaceutical Company Limited
ValiRx plc

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Endometriosis Drugs Market to Reach $3.3 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Endometriosis Drugs estimated at US$2.7 Billion in the year 2022, is projected to reach a revised size of US$3.3 Billion by 2030, growing at aCAGR of 2.6% over the period 2022-2030. Hormone therapy, one of the segments analyzed in the report, is projected to record 3% CAGR and reach US$2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Analgesics segment is readjusted to a revised 2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $777.8 Million, While China is Forecast to Grow at 2.4% CAGR

The Endometriosis Drugs market in the U.S. is estimated at US$777.8 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$580.1 Million by the year 2030 trailing a CAGR of 2.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.3% and 2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.

Select Competitors (Total 38 Featured):

AbbVie Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Bayer AG
Debiopharm Group
Evotec AG
Kissei Pharmaceutical Co. Ltd.
Neurocrine Biosciences Inc.
ObsEva SA
Pfizer Inc.
Repros Therapeutics Inc.
Takeda Pharmaceutical Company Limited
ValiRx plc

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Endometriosis: An Introductory Prelude
- Recent Market Activity
- Endometriosis Facts in a Nutshell
- Poor Efficacy & Safety Profiles of Existing Drugs Lead to Unmet Medical Needs
- Key Endometriosis Drugs on the Market
- The Pipeline Review
- Key Endometriosis Drugs in the Pipeline: 2017
- Endometriosis Drugs - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
- AbbVie Inc. (USA)
- Astellas Pharma Inc. (Japan)
- AstraZeneca Plc (UK)
- Bayer AG (Germany)
- Debiopharm Group (Switzerland)
- Evotec AG (Germany)
- Kissei Pharmaceutical Co., Ltd. (Japan)
- Neurocrine Biosciences, Inc. (USA)
- ObsEva SA (Switzerland)
- Pfizer, Inc. (USA)
- Repros Therapeutics, Inc. (USA)
- Roivant Sciences GmbH (Switzerland)
- Takeda Pharmaceutical Company Limited (Japan)
- ValiRx plc (UK)
3. MARKET TRENDS & DRIVERS
- Steady Growth Expected Over the Next Few Years
- Emerging Treatment for Endometriosis & Endometrial Cancer
- Global Awareness Campaigns and Efforts
- Uptrend in Healthcare Expenditure Creates Substantial Opportunities
- Developed Regions Remain Primary Revenue Contributors
- Developing Regions Exhibit Immense Growth Potential
- Stable Economic Scenario to Augment Market Prospects
4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Endometriosis Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Endometriosis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- TABLE 3: World Historic Review for Endometriosis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 4: World 16-Year Perspective for Endometriosis Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Hormone therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- TABLE 6: World Historic Review for Hormone therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 7: World 16-Year Perspective for Hormone therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- TABLE 9: World Historic Review for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 10: World 16-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030

III. MARKET ANALYSIS

UNITED STATES
- Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- TABLE 11: USA Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 12: USA Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 13: USA 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2023 & 2030
CANADA
- TABLE 14: Canada Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 15: Canada Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 16: Canada 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2023 & 2030
JAPAN
- Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- TABLE 17: Japan Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 18: Japan Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 19: Japan 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2023 & 2030
CHINA
- Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- TABLE 20: China Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 21: China Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 22: China 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2023 & 2030
EUROPE
- Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- TABLE 23: Europe Recent Past, Current & Future Analysis for Endometriosis Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- TABLE 24: Europe Historic Review for Endometriosis Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 25: Europe 16-Year Perspective for Endometriosis Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
- TABLE 26: Europe Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 27: Europe Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 28: Europe 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2023 & 2030
FRANCE
- Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- TABLE 29: France Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 30: France Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 31: France 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2023 & 2030
GERMANY
- Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- TABLE 32: Germany Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 33: Germany Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 34: Germany 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2023 & 2030
ITALY
- TABLE 35: Italy Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 36: Italy Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 37: Italy 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2023 & 2030
UNITED KINGDOM
- Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- TABLE 38: UK Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 39: UK Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 40: UK 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2023 & 2030
REST OF EUROPE
- TABLE 41: Rest of Europe Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 42: Rest of Europe Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 43: Rest of Europe 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2023 & 2030
ASIA-PACIFIC
- Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- TABLE 44: Asia-Pacific Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 45: Asia-Pacific Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 46: Asia-Pacific 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2023 & 2030
REST OF WORLD
- TABLE 47: Rest of World Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 48: Rest of World Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 49: Rest of World 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2023 & 2030